Eleonora M. Vromen
YOU?
Author Swipe
View article: Cerebrospinal fluid proteomic associations of <i>APOE</i> genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease
Cerebrospinal fluid proteomic associations of <i>APOE</i> genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease Open
BACKGROUND The apolipoprotein E ( APOE ) gene includes the strongest protective (ε2) and risk (ε4) variants for sporadic Alzheimer's disease (AD), but underlying mechanisms remain unclear. We studied APOE genotype effects on the cerebrospi…
View article: Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum
Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum Open
Importance The trajectories of core Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers and the concurrent cognitive changes across the clinical spectrum remain unclear yet are important for clinical trial design. Objective To map …
View article: CSF proteomic profiles related to cognitive decline in MCI A+ depend on tau levels
CSF proteomic profiles related to cognitive decline in MCI A+ depend on tau levels Open
Individuals with mild cognitive impairment (MCI) and an abnormal amyloid biomarker (A+) are at considerable increased risk of developing dementia. Still, these individuals vary greatly in rates of cognitive decline, and the mechanisms unde…
View article: Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting
Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting Open
Background The introduction of anti-amyloid treatments (AAT) for Alzheimer's disease (AD) has put the cost-effectiveness into focus. Objective Estimate the potential cost-effectiveness of diagnostic pathways combined with AAT for early AD.…
View article: Unraveling Alzheimer's disease heterogeneity:
Unraveling Alzheimer's disease heterogeneity: Open
CONCLUSION In conclusion, the heterogeneous nature of AD encompasses many aspects, including genetic factors, core biomarkers in CSF and disease trajectories. While core pathologies of AD include amyloid plaques and neurofibrillary tangles…
View article: CSF biomarkers trajectories across the AD spectrum reveal the temporal dynamics of amyloid and tau
CSF biomarkers trajectories across the AD spectrum reveal the temporal dynamics of amyloid and tau Open
Background The Alzheimer’s disease (AD) research framework proposes a biological definition of the disease. Still, little is known about longitudinal dynamics of core AD biomarker trajectories and how they map to each stage on the clinical…
View article: Distinct CSF proteomic signatures are associated with cognitive decline in A+T+ and A+T‐ individuals with MCI due to Alzheimer’s Disease
Distinct CSF proteomic signatures are associated with cognitive decline in A+T+ and A+T‐ individuals with MCI due to Alzheimer’s Disease Open
Background Individuals with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) show variability in cognitive decline. Little is known about the underlying mechanisms, but these are likely to depend on tau levels. Using untarge…
View article: Pooling Alzheimer's disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof‐of‐principle study and call to action
Pooling Alzheimer's disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof‐of‐principle study and call to action Open
With the advent of the first generation of disease‐modifying treatments for Alzheimer's disease, it is clearer now more than ever that the field needs to move toward personalized medicine. Pooling data from past trials may help identify su…
View article: Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles
Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles Open
View article: Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease
Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease Open
Background Brain innate immune activation is associated with Alzheimer’s disease (AD), but degrees of activation may vary between disease stages. Thus, brain innate immune activation must be assessed in longitudinal clinical studies that i…
View article: Automated FreeSurfer segmentation and visual quality control in 10,000 MRI scans from a large memory clinic cohort
Automated FreeSurfer segmentation and visual quality control in 10,000 MRI scans from a large memory clinic cohort Open
Background Automated image segmentation methods together with increasing computer power allow quantifying brain alterations in great detail in large neuroimaging datasets. The increasing size of data complicates visual quality control (QC)…
View article: Tau‐PET signal in Alzheimer’s disease is related to immune activation and synaptic signaling measured with CSF proteomics
Tau‐PET signal in Alzheimer’s disease is related to immune activation and synaptic signaling measured with CSF proteomics Open
Background Tau tangles are one of the pathological hallmarks of Alzheimer’s disease (AD) and can be quantified using PET. It remains unclear which molecular processes are related to tau aggregation. Protein levels in CSF can be used to stu…
View article: Longitudinal AD biomarkers in monozygotic twins: genetic contribution to AD biomarker concentrations over time
Longitudinal AD biomarkers in monozygotic twins: genetic contribution to AD biomarker concentrations over time Open
Background Understanding the earliest pathophysiological changes in Alzheimer’s disease (AD) is important for development of therapeutic intervention strategies. Studying genetically identical twins provides unique information on genetic a…
View article: Data‐driven analysis of most common neurodegenerative dementias reveals atrophy patterns associated with overlapping cognitive symptoms
Data‐driven analysis of most common neurodegenerative dementias reveals atrophy patterns associated with overlapping cognitive symptoms Open
Background A precise understanding of the neuroanatomical basis of clinical manifestation of dementia is an important step for timely diagnosis. Dementia due to proteinopathies, such as Alzheimer’s disease (AD), dementia with Lewy bodies (…
View article: CSF synapse marker changes in predementia Alzheimer´s Disease: AMPA receptor modulators NPTX2 and NPTXR mediate cognition within A/T/N stages
CSF synapse marker changes in predementia Alzheimer´s Disease: AMPA receptor modulators NPTX2 and NPTXR mediate cognition within A/T/N stages Open
Background Synapse pathology has been linked to excitotoxicity and glutamate receptor dysregulation (such as AMPAR) in Alzheimer´s Disease (AD) progression. Of the core cerebrospinal fluid (CSF) AD biomarkers for amyloid, tau pathology and…
View article: CSF Proteomic Signatures are Associated With Cognitive Decline in the Alzheimer’s Disease Continuum
CSF Proteomic Signatures are Associated With Cognitive Decline in the Alzheimer’s Disease Continuum Open
Background Individuals with Alzheimer’s disease (AD) show variability in cognitive decline. Little is known about the underlying biological processes. Using an untargeted CSF proteomics approach, we explored the biological processes associ…
View article: Pooling trial data to identify heterogeneity and characteristics of patients most likely to respond to treatment: a causal forest approach
Pooling trial data to identify heterogeneity and characteristics of patients most likely to respond to treatment: a causal forest approach Open
Background A potential explanation for the limited success of past therapeutic trials for Alzheimer’s disease (AD) lies in disease heterogeneity. We set out to pool and jointly analyze data from completed trials using a hypothesis‐free mac…
View article: Proteins involved in synapse organization are associated with longitudinal loss in gray matter network connectivity in prodromal AD
Proteins involved in synapse organization are associated with longitudinal loss in gray matter network connectivity in prodromal AD Open
Background Lower gray matter connectivity measures are related to faster cognitive decline in prodromal Alzheimer’s Disease (AD). We investigated the biological underpinnings responsible for this loss of brain connections using cerebrospin…
View article: Automated FreeSurfer segmentation and visual quality control in 10,000 MRI scans from a large memory clinic cohort
Automated FreeSurfer segmentation and visual quality control in 10,000 MRI scans from a large memory clinic cohort Open
Background Automated image segmentation methods together with increasing computer power allow quantifying brain alterations in great detail in large neuroimaging datasets. The increasing size of data complicates visual quality control (QC)…
View article: Large-scale cerebrospinal fluid proteomic analysis in Alzheimer’s disease patients reveals five molecular subtypes with distinct genetic risk profiles
Large-scale cerebrospinal fluid proteomic analysis in Alzheimer’s disease patients reveals five molecular subtypes with distinct genetic risk profiles Open
Alzheimer’s disease (AD) is heterogenous on the molecular level. Understanding this heterogeneity is critical for AD drug development. We aimed to define AD molecular subtypes by mass spectrometry proteomics in cerebrospinal fluid (CSF). O…
View article: Discovery of novel CSF biomarkers to predict progression in dementia using machine learning
Discovery of novel CSF biomarkers to predict progression in dementia using machine learning Open
View article: Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers Open
View article: Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study
Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study Open
The biological definition of Alzheimer’s disease using CSF biomarkers requires abnormal levels of both amyloid (A) and tau (T). However, biomarkers and corresponding cutoffs may not always reflect the presence or absence of pathology. Prev…
View article: Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers Open
Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer’s disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dem…
View article: Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline Open
Individuals with prodromal Alzheimer’s disease show considerable variability in rates of cognitive decline, which hampers the ability to detect potential treatment effects in clinical trials. Prognostic markers to select those individuals …
View article: CSF proteomic signature predicts progression to Alzheimer's disease dementia
CSF proteomic signature predicts progression to Alzheimer's disease dementia Open
Introduction Individuals in the Alzheimer's disease (AD) continuum with mild cognitive impairment (prodromal AD) are at increased risk to develop dementia. Still, underlying pathophysiological processes remain unclear. We studied whether c…